| Title |
Breakthrough cancer pain – still a challenge
|
|---|---|
| Published in |
Journal of Pain Research, November 2012
|
| DOI | 10.2147/jpr.s36428 |
| Pubmed ID | |
| Authors |
Cesar Margarit, Joaquim Juliá, Rafael López, Antonio Anton, Yolanda Escobar, Ana Casas, Juan Jesús Cruz, Rafael Galvez, Ana Mañas, Francisco Zaragozá |
| Abstract |
Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%). According to the American Pain Foundation, breakthrough pain is observed in 50%-90% of all hospitalized cancer patients, in 89% of all patients admitted to homes for the elderly and terminal-patient care centers, and in 35% of all ambulatory care cancer patients. The management of breakthrough cancer pain should involve an interdisciplinary and multimodal approach. The introduction of new fentanyl formulations has represented a great advance and has notably improved treatment. Among these, the pectin-based intranasal formulation adjusts very well to the profile of breakthrough pain attacks, is effective, has a good toxicity profile, and allows for convenient dosing - affording rapid and effective analgesia with the added advantage of being easily administered by caregivers when patients are unable to collaborate. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 60 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 15% |
| Student > Ph. D. Student | 8 | 13% |
| Other | 6 | 10% |
| Student > Master | 6 | 10% |
| Student > Bachelor | 4 | 6% |
| Other | 14 | 23% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 45% |
| Nursing and Health Professions | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 19 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2017.
All research outputs
#7,496,019
of 22,914,829 outputs
Outputs from Journal of Pain Research
#746
of 1,753 outputs
Outputs of similar age
#59,357
of 184,519 outputs
Outputs of similar age from Journal of Pain Research
#10
of 15 outputs
Altmetric has tracked 22,914,829 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,753 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.9. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,519 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.